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Results: 77/87 (88.5%) patients in our sample used alendronate as a BP type; the duration of bisphosphonate
therapy ranged from 2 to 200 months, and 51.7% of patients were in treatment for ≤38 months (median
value). No comorbidities or local risk factors were observed in 17 (19.5%) patients, indicating the absence of
cases belonging to BRONJ forms triggered by surgery. BRONJ localization was signiﬁcantly associated with age:
an increased risk of mandible localization (p = 0.002; OR = 6.36, 95%CI = [1.89; 21.54]) was observed
for those over 72 yrs. At multivariate analysis, the increased risk of BRONJ in the mandible for people over
72 yrs (OR′ = 6.87, 95%CI = [2.13; 2.21]) was conﬁrmed for a BP administration >56 months (OR′ = 4.82,
95%CI = [2.13; 22.21]).
Conclusion:Our study conﬁrms the fundamental necessity of applying protocols of prevention in order to reduce
the incidence of BRONJ in osteoporotic, non-cancer patients in the presence of comorbidities and/or local risk
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ation of Internal Medicine. Publishe1. Introduction
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is de-
scribed by Bedogni et al. [6] as an adverse drug reaction consisting of
the progressive destruction and death of bone that affects the mandible
ormaxilla of patients exposed to the treatmentwith nitrogen-containing
bisphosphonates, in the absence of a previous radiation treatment.
Clinically, the most frequent sign is bone exposure even if different
symptoms and minor signs (i.e. pain, hypoesthesia/paraesthesia, ﬁstula,
abscess, swelling, trismus) should raise suspicions of BRONJ. Early diag-
nosis is still essential for patients and clinicians, given the slight hope
of restitutio ad integrum in BRONJ patients.d by Elsevier B.V. All rights reserved.
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focus of the majority of papers [3,55] to date, whereas the impact of
BRONJ in non-cancer patients, with osteoporosis or Paget disease,
who receive lower doses of BPs is less known [34,37]. The estimated
prevalence of BRONJ in non-cancer (mainly osteoporotic) patients
may range from 0.02% to 11% [22–24,29,33,36,42,44,47,49].
Less uniform is thepercentage of BRONJ amongnon-cancer, osteopo-
rotic patients within whole samples also comprising cancer patients: in
a multi-center study, a BRONJ frequency of 7.1% in patients treated with
oral BP therapy [41]was reported; a frequency of 8.9% of BRONJ after per
os BP administrationwasobserved in two Israelimedical centers; and, of
all the BRONJ patients in other case series reported in the literature, the
percentage of orally-administered bisphosphonate-induced ONJ ranges
from 2.5% to 27.3% [58]. In the absence of reliable statistics indicating
the number of patients exposed to BPs, it is still not easy to establish
the real risk of developing BRONJ for non-cancer patients, also due to
the large number of supposed and still unascertained risk factors. More-
over, some authors indicate a notable under-reporting [25] while
afﬁrming that BRONJ is becoming more common [30].
Japanese authors [57] have recently identiﬁed a risk of b1% for
4129 patients regarding osteomyelitis of the jaw due to oral BP, un-
derlying that the use of BPs may increase the risk of osteomyelitis
more than with other osteoporosis medications. Other authors [12]
have recently described a total of 310 patients with BRONJ from oral
BP, after a Pub-Med-based search of case series with a minimum
number of 10 subjects. Reid and Cornish [42] have reported 261
cases of BRONJ in patients who had received oral BP, the majority of
whom were treated by the most widely used amino-BP (NBP), that
is, alendronate.
Turning to Italy, Lapi et al. [27] evaluated the association between
oral BPs prescribed for the secondary prevention of osteoporotic
fractures and the rate of BRONJ, discovering an incidence rate of
36.6 per 100,000 person-year. Vescovi et al. [54] published data
from a single-center experience in which 19.9% of cases of BRONJ in
non-oncological patients were described. An online report by the
Italian Drug Regulatory Agency (AIFA) observed 18% of BRONJ warn-
ings related to the use of BPs for osteoporosis in a period from 2001 to
2009 [50]. Favia et al. [16] analyzed a total of 24 BRONJ cases in
patients who underwent bisphosphonate therapy for non-cancer
disease over a 4 year period.
In our opinion it is necessary to ﬁll the following gaps in knowledge:
1) the incidence and the prevalence of BRONJ in non-cancer osteoporot-
ic patients taking oral NBP; and 2) the nature and entity of risk factors
for BRONJ in osteoporotics. BRONJ is capable of reducing QoL in osteo-
porotic patients and cancer outlives [38], as can be observed in the
later stages as: infected and painful necrotic jaw bone, ulcerated, pain-
ful, and swollen oral mucosa, chronic sinus tracts and facial deformity,
impaired speech, swallowing, and eating. QoL impairments for late
stages of BRONJ are similar to the side effects in cancer treatments.
The primary endpoints of the Italian multi-center, cross-sectional
study presented in this paper are: i) an observation of the clinical
features of BRONJ in 87 non-cancer osteoporotic patients; and ii) an
evaluation of their demographic variables and comorbidities.
2. Methods
2.1. Study design
A cross-sectional study was carried out between January 2004 and
December 2007 in eight Italian clinical centers (2 in the north of Italy,
1 in the center and 5 in the south).
2.2. Participants
We consecutively and unselectively included 92 osteoporotic
non-cancer patients with the following inclusion criteria:1) the presence of osteoporosis in therapy with BPs;
2) the presence of BRONJ according to the deﬁnition of the AAOMS
[46]; and
3) the presence of a non-exposed variant of BRONJ [17]
4) age ≥18 yrs.
The exclusion criteria were:
1) the presence of cancer alone or in concomitance; and
2) a history of radiotherapy to the head and neck region.
2.3. Outcomes
The following data were recorded: gender, age, steroid therapy and
comorbidities (e.g., diabetes and coagulopathy), type of BP adminis-
tered and formulation, site of each lesion, clinical BRONJ stage [46],
the duration of bisphosphonate therapy at BRONJ presentation, and
any potential precipitating event (e.g. dento-alveolar surgery, peri-
odontal disease). Every patient in the study provided informed consent
wasmethodically examined, and a completemedical historywas taken.
After clinical examination, all patients underwent radiological examina-
tions of the jaws (panoramic radiograph and CT), focusing particularly
on alterations of bone architecture with a loss of medullar bone,
trabeculation, or increased bone density [7,45].
2.4. Statistical methods
A statistical analysiswas conducted, considering two responses of the
study: BRONJ localization (coded as maxilla—reference, mandible, man-
dible and maxilla) and BRONJ stage coded according to AAOMS-Update
2009. The association with local and systemic variables was tested
using the χ2 test or Fisher's exact test, where appropriate. Crude Odds
Ratios (OR) and 95% Conﬁdence Intervals (CI) were calculated as associ-
ationmeasures. To obtain adjusted ORswith respective 95%CIs, themul-
tinomial logistic regression was applied to BRONJ localization and the
ordinal logit model was used to identify the BRONJ stage. If variables
were signiﬁcantly associated with the responses in the univariate analy-
sis, they were included in the multivariate models and the duration of
administration was included in both models due to its clinical relevance
in the study. The age variable was categorized with respect to the medi-
an of the analyzed sample. The duration of bisphosphonate administra-
tion was categorized into quartiles, and ≤24 months was chosen as a
reference category. Alendronate was chosen as the reference type of
administered bisphosphonate. A p value≤0.05was chosen for statistical
signiﬁcance and the data were analyzed using STATA MP, v. 11.0.
This multi-center study was approved by the Ethics Committee of
every unit or department involved and conducted according to the
Declaration of Helsinki.
3. Results
3.1. Participants
Data from 92 cases of BRONJ were collected: all patients were
female, ranging in age from 53 to 92 yrs (mean age ± standard devi-
ation 70.7 ± 9.7 yrs; median 72). Of this sample, we excluded ﬁve
(5.4%) patients from the study due to their off-label use of BP (3 for
i.m. zoledronate, 1 for i.v. zoledronate plus i.v. pamidronate, and 1
for i.v. pamidronate) and, after conﬁrmation of eligibility, we includ-
ed and analyzed 87 patients. Within this latter sample, we included
ﬁfteen cases (17.2%) in which BRONJ diagnostic criteria by AAOMS
(i.e. bone exposure sign) had not been totally matched and they
were at stage “0”, since at least one of the characteristics of the
non-exposed variant of jaw osteonecrosis was present (i.e. ﬁstula,
swelling, jawbone pain, mobile teeth, and mandibular fracture), as
deﬁned by Fedele et al. [17].
Table 2
Concomitance or not of systemic (S) and local (L) risk factors: number (%) of patients.
Concomitance of S and L 33(37.9)
Presence of S alone 9(10.4) Single 7(8.1) Multiple 2(2.3)
Presence of L alone Single 28(32.2) Multiple 0(0.0)
No presence of S and/or L 17(19.5)
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Postmenopausal osteoporosis was the main condition necessitating
BP therapy (84/87 patients, 96.5%), followed by corticosteroid-induced
osteoporosis (3/87, 3.5%). The variables considered are summarized in
Table 1.3.3. Main results
Forty-two patients (42/87, 48.3%) had various comorbidities (e.g.
diabetes mellitus, hypertension, HCV-related liver disease, cardiac dis-
eases); thirty-three (37.9%) of these had concomitant local risk factors
(Table 2). In twenty-eight cases (28/87, 32.2%) no comorbidities or
co-medication were recognized; for seventeen patients (19.5%) no
local risk factors or comorbidities were shown.
RegardingBP type, 77/87 (88.5%) patients used alendronate (aweekly
dose of 70 mgorally), 7 (8.1%) patients used clodronate (monthly dose of
600 mg i.m.), 2 (2.3%) patients risedronate (weekly dose of 35 mg orally)
and 1 (1.1%) ibandronate (3-monthly dose of 2 mg i.v.). Three patients
were treated with two different BPs over different periods, ﬁrstly with
alendronate, and then with clodronate. The mandible was affected
more frequently (61, 70.1%) than the maxilla (23, 26.4%), and three
patients (3.5%) presented multiple BRONJ events.
The most frequent sign at presentation was bone exposure
(82.8%), generally associated with pain and suppuration. BRONJ wasTable 1
Demographical data and outcomes.
BRONJ observed patients 92
Median age 72
Q1–Q3 62–79
BRONJ analyzed patients 87
Median age 72
Q1–Q3 61–79
Mean age ± SD 70.7 ± 9.8
n(%)
Gender
Female 87(100)
Male 0(0.0)
Corticosteroid therapy 3(3.5)
Comorbidities Yes
42(48.3)
No
45(51.7)
Diabetes 8(9.2)
Hypertension 35(40.2)
HCV-related liver diseases 1(1.2)
Other cardiac 10(11.5)
Type of administered BP
Alendronate 77(88.5)
Clodronate 7(8.1)
Risedronate 2(2.1)
Ibadronate 1(1.1)
Site of BRONJ
Mandible 61(70.1)
Maxilla 23(26.4)
Mandible and Maxilla 3(3.5)
BRONJ stage according to AAOMS-update 2009
Stage 0 15(17.2)
Stage 1 12(13.8)
Stage 2 53(60.9)
Stage 3 7(8.1)
Duration of bisphosphonate therapy at
BRONJ presentation (months)
Median duration 38
Q1–Q3 20–60
Precipitating event (local Risk factors for BRONJ) Yes
61(70.1)
No
26(29.9)
Tooth extraction 57(65.5)
Periodontal chronic disease and abscess 2(2.3)
Bone biopsy 0(0.0)
Prosthetic trauma 2(2.3)
Implantology 0(0.0)deﬁned and classiﬁed according to AAOMS [46], as follows: 15 patients
with stage 0 (17.2%), 12 patients with stage 1 (13.8%), 53 patients with
stage 2 (60.9%) and 7 patients with stage 3 (8.1%). The duration of
bisphosphonate therapy at presentation ranged from 2 to 200 months
(mean time ± standard deviation 44.9 ± 35.5 months; median
38 months, interquartile range = 20–60 months): 45 (51.7%) were
BRONJ patients in treatment for ≤38 months. Dento-alveolar surgery,
such as tooth extraction (due to dental/periodontal diseases), was the
most common triggering factor for BRONJ (57/87 patients; 65.5%);
two cases occurred in patients with ill-ﬁtting dentures (2.3%) and
other two cases occurred in patients with periodontal chronic disease
and abscess (2.3%).
BRONJ localization was signiﬁcantly associated only with age
(p = 0.002): for people over 72 yrs of age, an increased risk of man-
dible localization with respect to maxilla (OR = 6.36, 95%CI = [1.89;
21.54]) (Table 3) was observed. Noneof the comorbidities and local risk
factors for BRONJ were signiﬁcantly associatedwith localization or stage
at univariate analysis. At multivariate analysis, the increased risk of
mandible localization with respect to maxilla for people older than
72 yrs (OR′ = 6.87, 95%CI = [2.13; 2.21])was conﬁrmed for a duration
of administration >56 months (OR′ = 4.82, 95%CI = [2.13; 22.21]).
The BRONJ stage was not associated with the duration of administration
(Table 4).
4. Discussion
Bisphosphonates (BPs) are currently the main drugs for the
prevention/treatment of osteoporosis: BP per os formulation is
based on alendronate (the most widely prescribed), risendronate or
ibandronate; i.m. injection with clodronate, and since 2006, i.v. ther-
apy has been based on ibandronate, pamindronate or zoledronic acid.
As a chronic disease, osteoporosis generally requires the long-term
administration of BPs. Taking into account their beneﬁts, BPs have
been believed to conform to a safety proﬁle in the treatment of
osteoporosis [21]. Currently, women affected by osteoporosis, with
a life expectancy of 83.4 yrs, may be treated in western countries
(e.g. Italy) with BPs for many years [20], although a considerable con-
troversy regarding the ideal duration of BP therapy exists [9,10,56].
Of the adverse effects of BPs, BRONJ has also been recog-
nized in non-cancer patients affected by osteometabolic diseases
[22,23,29,36,42,44,47,49], but always impacting less than expected in
cancer patients. The real risk for patients in therapy with BPs for
osteometabolic diseases developing BRONJ is not really known, in part
due to the paucity of crucial information, such as the exact total number
of patients exposed to BP, and to the precise interplay of the high num-
ber of suspected risk factors implicated (Table 5).
Concurring with other authors [11–13,32,41], we observed and
described 87 cases of BRONJ in patients taking oral BPs; these cases
have been described and correlated with other cases [5,12,16,31],
mainly occurring in the mandible (73.6%). One limitation of our
research was the non-controlled study design which may have led
to an overestimation of BRONJ in non cancer-patients. There are
very few RCTs dealing with this issue [1,8,18,19,28,39,51].
It is our opinion that BRONJ should be under the constant attention
of all specialists who prescribe BPs for various reasons, be they to treat
cancer or not, even if it is well known that i.v. BPs for cancer patients
are more powerful than BPs for non-cancer patients (mainly per os).
Furthermore, the reporting of BP off-label use can be described as
Table 3
Association between BRONJ localization and local and systemic risk factors: Odds ratios and 95%CIs.
Risk factors for BRONJ Maxilla n = 23 Mandible n = 61 Mandible and Maxilla n = 3 pa
Age
b72 yrs old n(%)
OR
95%CIb
18(78.3)
1.00
22(36.1)
0.16
[0.05–0.53]
2(66.7)
0.56
[0.04–7.93]
0.002
≥72 yrs old n(%)
OR
95%CIb
5(21.7)
1.00
39(63.9)
6.36
[1.89–21.54]
1(33.3)
1.80
[0.13–25.70]
0.002
Duration of administration
≤24 months n(%)
OR
95%CIb
13(56.5)
1.00
17(22.9)
0.30
[0.11–0.84]
1(33.3)
0.38
[0.03–5.27]
0.050
From 24 to 56 months n(%)
OR
95%CIb
6(26.1)
1.00
21(34.4)
1.49
[0.50–4.38]
0(0.0)
0 (0.0)
–
0.379
>56 months n(%)
OR
95%CIb
4(17.4)
1.00
23(37.7)
2.88
[0.84–9.80]
2(66.7)
9.5
[0.53–171.48]
0.098
Local risk factors
Tooth extraction n(%)
OR
95%CIb
16(69.6)
1.00
39(63.9)
0.78
[0.27–2.19]
2(66.7)
0.88
[0.06–11.91]
0.889
Spontaneous BRONJ n(%)
OR
95%CIb
5(21.7)
1.00
20(32.8)
1.76
[0.56–5.49]
1(33.3)
1.80
[0.13–25.70]
0.609
Periodontal chronic disease and abscess n(%)
OR
95%CIb
1(4.4)
1.00
1(1.6)
0.37
[0.02–6.28]
0(0.0)
0 (0.0)
–
0.632
Prosthetic trauma n(%)
OR
95%CIb
1(4.4)
1.00
1(1.6)
0.37
[0.02–6.28]
0(0.0)
0 (0.0)
–
0.632
Comorbidity
Absent n(%)
OR
95%CIb
14(60.9)
1.00
29(47.5)
0.58
[0.22–4.62]
2(66.7)
1.29
[0.10–10.41]
0.480
Present n(%)
OR
95%CIb
9(39.1)
1.00
32(52.5)
1.72
[0.64–4.62]
1(33.3)
0.78
[0.06–10.41]
0.480
Type of BP
Alendronate n(%)
OR
95%CIb
20(87.0)
1.00
54(88.5)
1.16
[0.27–4.96]
3(100.0)
–
–
0.801
All others n(%)
OR
95%CIb
3(13.0)
1.00
7(11.5)
0.86
[0.20–3.70]
0(0.0)
–
–
0.801
a p-Values of χ2 test or Fisher's exact test, where appropriate.
b Default standard errors used for 95%CIs.
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similarly reported by others [43]. Generally, it is known that the use of
drugs for unapproved indications is common [14]: the absence of regu-
latory approval for treatment indication could mean that a drug should
be useful but adverse drug events, which may be less predictable, must
be taken in account. Our ﬁndings indicate that off-label prescription
should also be cautiously considered for this category of drugs.
In agreement with Malden and Lopes [31], we observed that the
88.5% of BRONJ patients were in therapy with alendronate, currentlyTable 4
Association between BRONJ localization and BRONJ stage with local and systemic risk facto
Variables BRONJ localization
Mandible vs maxilla
OR 95%CI p
Duration of BP administration
From 24 to 56 months 3.04 [0.85; 10.85] 0.086
>56 months 4.82 [1.21; 19.24] 0.026
Age
>72 yrs old 6.87 [2.13; 22.21] 0.001
a 95%CI not calculable.the most prescribed drug for osteoporosis. Given the current scarcity
of a database involving a large number of people, it is not possible to
establish “true” risk factors, apart from age, gender, steroid, and type
of BP [26]. Authors have described in the literature the concomitant
presence of comorbidities and/or so called-trigger (local) factors
[53] (e.g. tooth extraction due to dental/periodontal diseases and
dental/periodontal diseases) in many cases of BRONJ, also in osteopo-
rotic non-cancer patients, where the potency and quantity of NBP is
lower. Nearly half (48.3%) of the patients in our study displayed thers: odds ratios and 95%CIs, p-values.
BRONJ stage
Mandible and maxilla vs maxilla
OR 95%CI p OR 95%CI p
0.00a 0.991 2.1 [0.72; 6.10] 0.174
6.77 [0.47; 95.04] 0.161 0.79 [0.30; 2.13] 0.649
1.85 [0.13; 26.08] 0.647
Table 5
Most relevant studies (>10 cases) of BRONJ in osteometabolic patients.
Authors (ref) No. Gender Mean age
[yrs] (range)
BP type (no.) Mean time
[months] of
administration
Motivation for BP
therapy (no.)
Patients taking
corticosteroids
Comorbidities (no.) Lesion
site (no.)
Trigger event (no.)
Marx et al. [59] 30 30 F 64.8 (NA) A (27)
R (3)
67 Osteopenia (16)
Osteoporosis (14)
NA Rheumatoid
arthritis (3)
Md (29)
Mx (1)
Dental extraction (15)
Spontaneous (15)
Yarom et al. [58] 11 11 F 69.7 (55–79) A (11) 49 Osteoporosis (9) 1 Rheumatoid
arthritis (2)
Hypothyroidism (3)
Md (8)
Mx (3)
Dental extraction (7)
Dental implant (2)
Dental trauma (2)
Favia et al. [16] 24 24 F 71.5 (53–83) A (15)
C (3)
R (2)
I (2)
A + C (1)
C + R (1)
20 Osteoporosis (9)
Orthopedic
surgery (2)
3 Diabetes (1)
Cryoglobulimenia (1)
Arterial
hypertension (7)
Md (21)
Mx (9)
Dental extraction (18)
Dental implant (4)
Periodontal disease (5)
Apical lesion (1)
Spontaneous (11)
Lazarovici et al. [60] 16 NA NA A (16) 67 Osteoporosis (16) NA NA NA NA
Otto et al. [4] 37 30 F
7 M
68.7 (46–88) A (28)
R (4)
I (3)
C (1)
A + R (1)
57 Osteoporosis (37) NA NA NA NA
Manfredi et al. [32] 25 25 F 70.4 (65–85) A (12)
I (1)
C (1)
N (1)
A + I (3)
A + C (2)
A + R (2)
NA Osteoporosis (25) 9 Rheumatoid
arthritis (4)
Diabetes (4)
Md (16)
Mx (9)
Dental extraction (16)
Dental implant (2)
Spontaneous (7)
Malden and Lopes [31] 11 9 F
2 M
69 (48–83) A (16) 36 Osteoporosis (7) 4 Rheumatoid
arthritis (4)
Diabetes (1)
Cardiac
conditions (7)
Respiratory
conditions (2)
Md (8)
Mx (3)
Dental extraction (7)
Dental trauma (2)
Spontaneous (2)
Diniz-Freitas et al. [12] 20 19 F
1 M
71.2 (53–82) A (16)
I (4)
66 Osteoporosis (17) 7 Rheumatoid
arthritis (3)
Diabetes (5)
Arterial
hypertension (12)
Osteoarthritis (3)
Hypothyroidism (2)
Md (16)
Mx (6)
Dental extraction (15)
Dental implant (2)
Apical lesion (1)
Spontaneous (6)
Present paper 87 87 F 70.7 (53–92) A (77)
R (2)
I (1)
C (7)
44.9 Osteoporosis (87) 3 Rheumatoid
arthritis (3)
Diabetes (8)
Arterial
hypertension (35)
Cardiac
conditions (10)
Md (64)
Mx (26)
Dental extraction (57)
Periodontal disease (2)
pProsthetic trauma (2)
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local risk factor was present; concomitant comorbidities and triggers
were observed in 37.9% of patients. This point is very important and it
should also be taken into account in relation to BRONJ prognosis.
O'Ryan and Lo [40] have recently observed that BRONJ patients taking
oral BPs and with relevant comorbidities demonstrated a lower prob-
ability of healing and a longer median time in healing than patients
without comorbidities.
On the other hand, we also wish to underline the observation in
almost 20% (17/87) of “true spontaneous” BRONJ, whereby it was not
possible to detect any potential systemic risk factors, comorbidities or
local risk factors. This datum is of great interest to researchers and it
could mean that BRONJ may occur without known risk factors. More-
over, it would be interesting to identify further risk factors hitherto un-
known. Noteworthy is our opinion that the expression spontaneous
BRONJ has been used incorrectly in the literature [40] since it is often
being employed in cases of BRONJ unrelated to a surgical procedure
(e.g. extraction due to dental/periodontal disease), but without specify-
ing the presence or not of comorbidities or other trigger mechanisms.
The drug dose and the cumulative dose play a role in the initiation
of necrosis, as well as the speciﬁc type of BP used [4]. Even if thelonger-term use of oral BPs should have a dose equivalence effect
[48], it is notable that the mean time of presentation was approxi-
mately 3 yrs (38 months) in the patients in this study, as already de-
scribed in the literature [12,16,35]. Such a fact would indicate that the
short time period of BP exposure may not always necessarily consti-
tute a safety threshold relating to the risk of BRONJ in any given pa-
tient and, in every case, the tailoring of BP therapy to individual
patients would be beneﬁcial. The most frequent observation in our
sample of the AAOMS stage 2 BRONJ (60.9%) correlates with the
data reported in other studies [5,12,16,31]. It is our opinion that this
frequent datum is relevant to explaining the incidence of a tardy
BRONJ diagnosis, either due to delay, a misdiagnosis or a low level
of awareness by the physician.
A primary goal should be to preserve or to obtain the status of
good oral health, regardless of the duration of BP treatment.
According to the European Medicines Agency (EMEA)[15], a dental
examination is advised in non-cancer patients prior to commencing
BP therapy, only if the dental status has been evaluated as poor.
Paradoxically, the manner of evaluating dental status is not speciﬁed
by the EMEA. In this regard, the Italian Society of Oral Medicine and
Pathology has published an online questionnaire with the aim of
789O. Di Fede et al. / European Journal of Internal Medicine 24 (2013) 784–790helping the practitioner to establish if the patient's dental status is
poor and if s/he requires a specialist dental examination (http://
www.sipmo.it/), as advised by the EMEA.
According to Loukota [30], the BRONJ phenomenon is growing
exponentially and we believe that the requisite of preventing local
risk factors (e.g. tooth extraction to dental/periodontal diseases and
dental/periodontal diseases) is unquestionable, also when BP should
be prescribed for non-cancer indications. Recently, other Italian
authors [2] have underlined the necessity of increasing the knowl-
edge and adequate reporting of the BRONJ phenomena by health
professionals, and of improving the elaboration of effective BRONJ
preventive protocols [52], in order to minimize as far as possible the
severe adverse effects of such an efﬁcacious medical treatment.
In conclusion, it is our opinion that the administration of oral BP,
particularly in excess of 2.5–3 yrs, should be responsibly considered.
The relevance of this is that the serious adverse effects associated
with oral BP (such as BRONJ and atypical femur fracture) are still
being reported (and not so infrequently). In this scenario, cumulative
BP-doses will hopefully be tailored to patients' needs and conse-
quently a higher degree of general safety attained. Another strategy,
also concomitantly, should be to reach and to maintain good oral
health, by means of adequate protocols of primary and secondary
prevention, especially for prolonged BP therapies in individuals with
comorbidities.
Learning points
• All authors consider essential the observation of all patients before
and in therapy with bisphosphonates (cancer and not) since in litera-
ture many reports of BRONJ (Bisphosphonate related osteonecrosis of
the jaws) in osteoporotic patients are present.
• The application of prevention protocols also in osteoporotic patients
could reduce the risk of BRONJ.
• Also in absence of known risk factors, the spontaneous BRONJ is
almost 20% in our sample: it couldmean that it is essential to proceed
with the identiﬁcation of further risk factors hitherto unknown.Conﬂict of interest
All of the authors have no ﬁnancial interest or other relationships
in the material.
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